Solubilization and amorphization of non steroidal anti-inflammatory drug with low molecular weight chitosan for a new guar-based colon delivery formulation

Letters in Drug Design and Discovery

Volumn 8, Issue 3, 2011, Pages 292-301

  Elkhodairy, Kadria A ^a   Barakat, Nahla S ^a   Alanazi, Fars K ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Department of Pharmaceutical Industries ^*  (Saudi Arabia)

Author keywords

Binary mixtures; Chitosan; Etodolac; Film coating; Guar gum

Indexed keywords

CHITOSAN; ETODOLAC; GUAR GUM;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; FILM COATING; MOLECULAR WEIGHT; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION;

EID: 79952291834     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011794578141     Document Type: Article

References (45)

1. Yang, L.; Chu, J.S.; Fix, J.A. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int. J. Pharm., 2002, 235, 1-15.
2. Halsas, M.; Penttinen, T.; Veski, P.; Jurjenson, H.; Marvola, M.; Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlation. Pharmazie, 2001, 56, 718-723.
3. Haslas, M.; Hietala, J.; Veski, P.; Jurjenson, H.; Marvola, M. Morning versus evening dosing of ibuprofen using conventional and time-controlled release formulations. Int. J. Pharm., 1999, 189, 179-185.
4. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer, E.J.; Thun, M. Cancer statistics, 2005. CA Cancer J. Clin., 2005, 55(1), 10-30.
5. Janne, P; Mayer, R. Chemoprevention of colorectal cancer. N. Engl. J. Med., 2000, 342, 1960-1968.
6. Gupta, R. A.; DuBois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev., 2001, 1, 11-21.
7. Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Up-regulation of cyclooxygenase-2 gene expression in human and colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107, 1183-1188. (Pubitemid 24294584)
8. Fujita, T.; Matsui, M.; Takaku, K. Size-and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res., 1998, 58, 4823-4826. (Pubitemid 28503676)
9. El-Kamel, A.H.; Abdel-Aziz, A.A.; Fatani, A. J.; El-Subbagh, H.I. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment. Int. J. Pharm., 2008, 358(1-2): 248-255.
10. Asghar, L. F.; Chandran, S. Design and evaluation of pH modulated controlled release matrix systems for colon specific delivery of indomethacin. Pharmazie, 2008, 63(10), 736-742.
11. Krishnaiah, Y.S.; Satyanarayana, V.; Kumar, B.D.; Karthikeyan, R.S. Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. Drug Targe., 2002, 10(3), 247-254. (Pubitemid 34467294)
12. Takeda, J.; Kitajima, K.; Fujii, S.; Horiuchi, H.; Hori, H.; Chibana, Y.; Okuyama, T.; Tominaga, K.; Ichikawa, K.; Ono, Y.; Teramoto, T.; Ohkura, Y.; Imura, J.; Shinoda, M.; Chiba, T.; Sakamoto, C.; Kawamata, H.; Fujimori, T. Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats. Oncol. Rep., 2004, 11(5), 981-985.
13. Carson, D.A.; Cottam, H.B.; Adachi, S.; Leoni, L.M. Use of etodolac for the treatment of prostate cancer. United States Patent 710556, 2006.
14. Mishima, K.; Nariari, Y.; Yoshimura, Y. Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression. Oral Oncol., 2005, 4, 77-81.
15. Yanaoka, K.; Oka, M.; Yoshimura, N.; Deguchi, H.; Mukoubayashi, C.; Enomoto, S.; Maekita, T.; Inoue, I.; Ueda, K.; Utsunomiya, H.; Iguchi M, Tamai H, Fujita shiro, Nakamura Y, Tsukamoto T, Inada K, Takeshita T, Ichinose M. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylorinegative precancerous lesion. Int. J. Cancer, 2010, 126(6), 1467-1473.
16. Okamoto, A.; Shirakawa, T.; Bito, T.; Shigemura, K.; Hamada, K.; Gotoh, A.; Fujisawa, M.; Kawabata, M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-Cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology, 2008, 71(1), 156-160.
17. th ed., 1999.
18. Lobenberg, R.; Amidon,G. L. Modern bioavailability, Bioequivalence and Biopharmaceutics Classification System. New Scientific Approaches to International Regulatory Standards. Eur. J. Pharm. Biopharm., 2000, 50, 3-12.
19. Ozkan, Y.; Doganay, N.; Diknen, K.; Isimer, A. Enhanced release of solid dispersion of etodolac in polyethylene glycol. Farmaco, 2000, 55, 433-438.
20. Brunella, C.; Clelia, di M.; Maria, L.; Agnese, M.; Antonio, C. Etodolac/cyclodextrin formulation:physicochemical characterization and in vivo pharmacological studies. Drug. Dev. Ind. Pharm., 2009, 35, 877-886.
21. Sinha, V. R.; Amita, R.C.; Honey, G. Enhancing the dissolution of hydrophobic guests using solid state inclusion complexation: characterization and in vitro evaluation. J. Incl. Phenom. Macrocycl. Chem., 2010, 66, 3-4.
22. Barakat, N. S. Enhanced oral bioavailability of Etodolac by self-emulsifying system: in vitro and in vivo evaluation. J. Pharm. Pharmacol., 2010, 62, 173-180.
23. st century. STP Pharma. Sci., 2000, 10, 5-22.
24. Portero, A.; Remunan-Lopez, C.; Vila-Jato, J. L. Effect of chitosan and chitosan glutamate enhancing the dissolution properties of the poorly water soluble drug nefedipine. Int. J. Pharm., 1998, 175, 75-84.
25. Mishra, D.N.; Kumar, S.G.V.; Zerrouk, N.; Mennini. N.; Maestrellis, F.; Chemtob, C. Development and characterization of naproxen-chitosan solid systems with improved drug dissolution properties. Eur. J. Pharm. Sci., 2003, 19, 67-75.
26. Mutalik, S.; Anju, P.; Manoj, K.; Usha, A.N. Enhancement of dissolution rate and bioavailability of aceclofenac: A chitosan-based solvent change approach. Int. J. Pharm., 2008, 350, 279-290.
27. Mishra, D.N.; Kumar, S.G.V. Preparation, Characterization and in vitro dissolution studies of solid systems of valdecoxib with chitosan. Chem. Pharm. Bull., 2006, 54, 1102-1106.
28. Fukuda, M.; Peppas, N.A.; McGinity, J.W. Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. Int. J. Pharm., 2006, 310, 90-100.
29. Rama Prasad, Y.V.; Krishnaiah, Y.S.R.; Satyanarayana, S. In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J. Control. Release, 1998, 51, 281-287.
30. Krishnaiah, Y.S.R.; Satyanarayana, S.; Rama Prasad, Y.V.; Narasimha Reo, S. Evaluation of guar gum as a compression coat for drug targeting to colon. Int. J .Pharm., 1998, 171, 137-146.
31. Krishnaiah, Y.S.R.; Bhaskar Reddy, P.R.; Satyanarayana, V.; Karthikeyan, R.S. Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int. J. Pharm., 2002, 236, 43-55.
32. Krishnaiah, Y.S.; Satyanarayana, V.; Dinesh Kumar, B.; Karthikeyan, R.S. In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur. J. Pharm .Sci ., 2002, 16(3),185-192.
33. Rane, S.; Kale, V. Evaluation of modified guar gum as film coating material. Int. J. Chem. Tech. Res., 2009, 1, 180-182.
34. Higuchi, T.; Connors, K. A. Phase solubility techniques. Adv. Anal. Chem. Instr., 1965, 4, 117-210.
35. Tobiska, S.; Kleinbudde, P. Coating uniformity: influence of atomizing air pressure. Pharm. Dev. Technol., 2003, 8, 39-46.
36. Bodek, K. H. Effect of Microcrystalline Chitosan on the Solubility of Ibuprofen. Acta. Polon. Pharm.-Drug. Res., 2002, 59, 105-108.
37. Najib, N. M.; Suleiman, M. S. Characterization of a diflunisal polyethylene glycol solid dispersion system. Int. J. Pharm., 1989, 51, 225-232.
38. Ba̧k, G. W.; Bodek, K. H.; Hilczer, B.; Pawłowski, T. Thermal Ageing Phenomena in Chitosan-related Pharmaceutical Systems, IEEE Trans. Dielectr. Electr. Insulat., 2001, 8, 555-558. (Pubitemid 32680723)
39. rd ed., Wiley, New York, 1976.
40. Sawayanagi, Y.; Nambu, N.; Nagai, T. Dissolution properties and bioavailability of griseofulvin from ground mixtures with chitin or chitosan. Chem. Pharm. Bull., 1982, 30, 4454-4467.
41. Sawayanagi, Y.; Nambu, N.; Nagai, T. Dissolution properties and bioavailability of phenytoin from ground mixtures with chitin or chitosan. Chem. Pharm. Bull., 1983, 31, 2062-2068.
42. Acerturk, F.; Sencan, A.; Celebi, N. Enhancement of the dissolution of spiranolactone with chitosan and low molecular weight gelatin. STP Pharma. Sc., 1993, 3, 369-373.
43. Acerturk, F,; Sencan. A.; Celebi, N. Evaluation of the effect of low molecular weight chitosan on the solubility and dissolution characteristics of spiranolactone. Pharmazie, 1993, 48, 605-607. (Pubitemid 23274787)
44. Mura, P.; Zerrouk, N.; Mennini, N.; Maestrellis, F.; Chemtob, C. Development and characterization of naproxen-chitosan solid systems with improved drug dissolution properties. Eur. J. Pharm. Sci., 2003, 19, 67-75.
45. Gittings, M. R.; Cipelletti, L.; Trappe, V.; Weitz, D. A. The effect of solvent and ions on the structure and rheological properties of Guar solutions. J. Phys. Chem., 2001, 105, 9310-9315.